why choose us

First received: July 05, 2023

Clinical Trial: Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Mycosis Fungoides

Study Type: INTERVENTIONAL


Official Title: Phase I Study With an Expansion Cohort of Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome

Brief Summary: The hypotheses of this study are that single agent CPI-0209 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, CPI-0209 will demonstrate efficacy and be worth of further study.

Read more